• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login

    Investing News NetworkYour trusted source for investing success

    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Medical Device Market
    Medical Device News
    Medical Device Stocks
    • Medical Device Market
    • Medical Device News
    • Medical Device Stocks
    1. Home>
    2. Life Science Investing NewsMedical Device Investing>
    Loading...
    0

    BlinkLab Completes First Patient Test for US Autism Diagnostic Study

    Gabrielle De La Cruz
    Mar. 13, 2025 09:25AM PST

    The study aims to validate BlinkLab’s Dx1 test, an artificial intelligence-powered neurological assessment designed to support the early detection of developmental conditions such as autism.

    illustration of brain and cell phone.
    smshoot / iStock

    Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

    BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

    The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.


    "Launching our US trial marks a very special and important moment for BlinkLab. Our mission has always been to connect fundamental neuroscience with clinical practice through accessible technology, thereby enhancing autism diagnostic evaluations and enabling early intervention for children,” said CEO and Co-founder Dr. Henk-Jan Boele.

    According to BlinkLab, the American Academy of Pediatrics advises that all children be screened for autism at 18 to 24 months. This is to refrain from delays in diagnosis, as many children miss critical windows for early intervention.

    Dx1’s goal is to address these delays by helping healthcare providers deliver faster and more reliable assessments. The smartphone-based platform uses artificial intelligence to measure sensory sensitivity.

    “After extensive app and portal development, stimulus refinement, and testing in hundreds of children, we are very confident in our (Food and Drug Administration) study's potential," Boele added.

    Results from the targeted 100 participant study are scheduled for release in the third quarter of 2025. The trial will proceed to the main study thereafter, which aims to test 750 to 900 children.

    BlinkLab’s submission for FDA 510(k) clearance is anticipated in 2026.

    In 2023, privately held EarliTec Diagnostics came up with a similar innovation for autism detection. The company's creation focuses more on social-visual engagement, evaluating a child’s looking behaviour.

    Currently, BlinkLab is the only ASX-listed company focusing on providing autism detection services or applications.

    Don’t forget to follow us @INN_Australia for real-time news updates!

    Securities Disclosure: I, Gabrielle de la Cruz, hold no direct investment interest in any company mentioned in this article.

    Editorial Disclosure: BlinkLab is a client of the Investing News Network. This article is not paid-for content.

    From Your Site Articles
    • How to Invest in Medical Devices ›
    • What Do Medical Device Companies Do? ›
    • 2 Biggest Medical Device ETFs in 2025 ›
    • Top 5 Small-cap Medical Device Stocks (Updated January 2025) ›
    • Medical Device Stocks: 5 Biggest Companies ›
    ASX:BB1
    https://x.com/biewritesnews
    https://www.linkedin.com/in/gabrielle-de-la-cruz-8582ba1bb/
    gdelacruz@investingnews.com
    The Conversation (0)
    Go Deeper
    AI Powered
    Row of test tubes and pipette with chemical droplet chemical coming from it.

    Top 5 Small-cap Biotech Stocks of 2025

    Pharma Outlook

    Pharma Outlook

    Gabrielle De La Cruz

    Gabrielle De La Cruz

    Writer

    Gabbie graduated with a journalism degree from Colegio de San Juan de Letran - Manila and has produced articles on a variety of topics, such as infrastructure, business and technology. Her creative portfolio includes written work on architecture, art and design. Gabbie covers the Australian market for the Investing News Network, focusing on the mining sector.

    When not in front of her desk, she is out scanning through vinyl records, exploring the international coffee culture and fighting for queer rights.

    Latest News

    More News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Medical Device Investing Stocks

    Cardiex Limited

     
    CDX:AU
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    Ă—
    Gabrielle De La Cruz

    Gabrielle De La Cruz

    Writer

    Gabbie graduated with a journalism degree from Colegio de San Juan de Letran - Manila and has produced articles on a variety of topics, such as infrastructure, business and technology. Her creative portfolio includes written work on architecture, art and design. Gabbie covers the Australian market for the Investing News Network, focusing on the mining sector.

    When not in front of her desk, she is out scanning through vinyl records, exploring the international coffee culture and fighting for queer rights.

    Full Bio

    Follow

    Learn about our editorial policies.